期刊文献+

Excel支架和Cypher支架治疗弥漫病变的对比研究 被引量:3

Comparison of Excel Stents and Cypher Stents for Treating the Patients With Diffuse Coronary Lesions
下载PDF
导出
摘要 目的:评价弥漫冠状动脉病变置入Excel支架(长度=36 mm)和Cypher支架(长度=33 mm)的安全性和有效性。方法:研究对象为2010-01至2011-12我院的316例置入Excel支架(长度=36 mm,Excel支架组)和315例Cypher支架(长度=33 mm,Cypher支架组)的冠心病患者,比较置入两种支架的患者临床特征、操作特点及主要不良心脏事件(包括死亡、心肌梗死和靶病变血运重建)。结果:在病变特点方面,与Cypher支架组相比,Excel支架组右冠状动脉病变(P<0.001)、近段血管极度扭曲病变(P<0.05)、病变成角>45°(P<0.01)比例较高,左前降支病变(P<0.001)、分叉病变(P<0.05)比例较低。在操作特点方面,Excel支架组支架总长度、平均支架数明显高于Cypher支架组(P<0.001)。操作成功率和血管径路并发症发生率差异无统计学意义(P>0.05)。两组12个月主要不良心脏事件发生率、心肌梗死的发生率、死亡率靶病变血运重建率差异无统计学意义(P>0.05)。结论:与Cypher支架(长度=33 mm)相比,弥漫长病变植入Excel支架(长度=36 mm)临床疗效类似,但极度扭曲病变、成角>45°病变置入长Excel支架更多见。 Objective: To compare the safety, efficacy of Excel stents and Cypher stents in treating the patients with diffuse coronary lesions. Methods: We retrospectively studied 631 patients with diffuse coronary lesions who were treated in our hospital from January 2010 to December 2011by implanting Excel stents (length=36mm) as Excel group, n=316, and Cypher stents (length=33mm) as Cypher group, n=315. We compared the clinical and procedural characteristics and the major adverse cardiac events (MACE) including death, myocardial infarction (MI) and target lesion revascularization (TLR) between 2 groups. Results: For lesion characteristics, compared with Cypher group, the Excel group had obviously increased right coronary lesion, P〈0.001, severe tortuous lesion in proximal vessels, P〈0.05, angular lesion〉45 degree, P〈0.01 and significantly decreased left anterior descending lesion, P〈0.001, bifurcation lesion, P〈0.05. For procedural characteristics, the Excel group had longer total stent's length and more number of stents, P〈0.001. There were no real differences for procedural success rate, vascular complication rate, and no real differences of MACE between 2 groups, P〉0.05 respectively. Conclusion: Our work indicated that both Excel stents (length=36mm) and Cypher stents (length=33mm) had similar effect for diffuse long coronary lesions in clinical practice, while Excel stent implantation were more used for severe tortuous lesion and angular lesion 〉45 degree.
出处 《中国循环杂志》 CSCD 北大核心 2013年第7期494-497,共4页 Chinese Circulation Journal
关键词 冠状动脉疾病 经皮 经腔 冠状动脉成形术 弥漫病变 支架 Coronary artery disease Percutaneous coronary intervention Diffuse lesions Stent
  • 相关文献

参考文献13

  • 1Spaulding C, Daemen J, Boersma E, et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med, 2007, 356: 989-997.
  • 2Marroquin OC, Seizer F, Mulukutla SR, et al. A comparison of bare- metal and drug-eluting stents for off-label indications. N Engl J Med, 2008, 358: 342-352.
  • 3Groeneveld PW, Matta MA, Greenhut AP, et al. Drug-eluting compared with bare-metal coronary stents among elderly patients. J Am Coll Cardiol, 2008, 51: 2017-2024.
  • 4Carlsson J, James SK, Lindback J, et al. Outcome of drug-eluting versus bare-metal stenting used according to on- and off-label criteria. J Am Coll Cardiol, 2009, 53: 1389-1398.
  • 5Degertekin M, Arampatzis CA, Lemos PA, et al. Very long sirolimus- eluting ster-t implantation for de novo coronary lesions. Am J Cardiol, 2004, 93: 826-829.
  • 6Kim YH, Park SW, Lee CW, et al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions. Catheter Cardiovasc Interv, 2006, 67: 181-187.
  • 7Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol, 2004,43: 1110-1115.
  • 8Han Y, Jing Q, Li Y, et al. Sustained clinical safety and efficacy of a biodegradable-polymer coated sirolimus-eluting stent in "real-world" practice: three-year outcomes of the CREATE (Multi-Center Registry of EXCEL Biodegradable Polymer Drug Eluting Stents) study. Catheter Cardiovasc lnterv, 2012, 79:211-216.
  • 9韩雅玲,鄢高亮,荆全民,李毅,王守力,马颖艳,刘海伟,栾波,王耿,王祖禄,王冬梅.EXCEL可降解涂层雷帕霉素洗脱支架长期临床应用的安全性和有效性[J].中国循环杂志,2010,25(2):88-91. 被引量:9
  • 10罗彤,邱洪,阮英茆,袁卫民,田毅,陈雪生,周燕文,钱鑫,孟亮,褚雁,徐新林,高润霖.可降解与非降解聚合物涂层雷帕霉素洗脱支架置入小型猪冠状动脉后的对比研究[J].中国循环杂志,2010,25(5):387-390. 被引量:5

二级参考文献21

  • 1邱洪,高润霖,唐智荣,孟亮,兆恒,阮英卯,赵红,杨跃进,陈纪林,陈在嘉.Mytrolimus药物洗脱支架预防支架内再狭窄的实验研究[J].中华心血管病杂志,2005,33(6):561-564. 被引量:15
  • 2Grines CL, Bonow RO,Casey DE, et at. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation,2007,115 : 813-818.
  • 3Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet ,2007,369:667-678.
  • 4Jose M, Torre H, Alfonso F, et al. Drug-eluting stent thrombosis : resuits from the multicenter Spanish registry ESTROFA (Estudio ESpanol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol,2008 ,51:986-990.
  • 5Carter AJ, Aggarwal M, Kopia GA, et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model. Cardiovasc Res ,2004,63:617-624.
  • 6Hong MK,Mintz GS,Whan CL,et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation ,2006,113:414-419.
  • 7Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS) : a randomised non-inferiority trial. Lancet, 2008,372 : 1163-1173.
  • 8Sanchez-Recalde A, Moreno R, Barreales L, et al. Risk of late-acquired incomplete stent apposition after drug-eluting stent versus bare-metal stent. A meta-analysis from 12 randomized trials. J Invasive Cardiol,2008,20(8) :417-422.
  • 9Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation ,2004,109:701-705.
  • 10Pfisterer M, Brunner HP, Buser PT, et al. BASKET-LATE investigators. late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol,2006,48:2584-2591.

共引文献12

同被引文献7

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部